Clearside Biomedical’s (CLSD) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research report report published on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $4.00 price objective on the stock. Several other equities analysts have also weighed in on CLSD. StockNews.com lowered shares of […]
More Stories
Top 11 Hottest News Anchors in the World of All Time
News anchors have become a part of global personality. They are no longer just people who read headlines. Now, viewers...
OpenAI Looking to Hire ‘Head of Preparedness’ to Tackle AI Dangers
By Naveen Athrappully OpenAI is seeking to hire a candidate for the post of “Head of Preparedness” to tackle dangers...
Washington Offers 15-Year Security Guarantee to Ukraine as Part of Peace Plan, Zelenskyy Says
By Guy Birchall Washington has offered a 15-year security guarantee to Kyiv as part of a proposed peace plan, Ukrainian...
Kremlin Says Ukraine Tried to Attack Putin’s Residence, Peace Deal Stance Under Review
By Jack Phillips Ukrainian forces attempted to strike Russian President Vladimir Putin’s residence in the Russian city of Novgorod on...
BofA CEO Calls Economy ‘Pretty Solid’ but Warns Consumer Pullback Is Top Risk for 2026
By Tom Ozimek U.S. economic growth remains on solid footing heading into 2026, but the outlook hinges on whether American...
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...